NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-CA-19-033 from the NIH Guide for Grants and Contracts
Notice NOT-NS-19-049 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-090 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-008 from the NIH Guide for Grants and Contracts
Notice NOT-DA-19-061 from the NIH Guide for Grants and Contracts
Notice NOT-AA-19-013 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-089 from the NIH Guide for Grants and Contracts
Notice NOT-GM-19-025 from the NIH Guide for Grants and Contracts
Notice NOT-HL-19-678 from the NIH Guide for Grants and Contracts
Notice NOT-GM-19-021 from the NIH Guide for Grants and Contracts
Notice NOT-HL-19-677 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-032 from the NIH Guide for Grants and Contracts
Notice NOT-TR-19-017 from the NIH Guide for Grants and Contracts
Notice NOT-FD-19-008 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-19-034 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. Furthermore, all research projects must be focused upon knowledge of human biology with a translational human endpoint proposed. All P20 grants must include a minimum of two well-developed translational research projects, as well as contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research activities with other institutions, P20 awardees, and/or current SPORE grantees
Notice NOT-NS-19-043 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HD-20-004 from the NIH Guide for Grants and Contracts. This is the renewal of a Funding Opportunity Announcement (FOA), issued by NICHD, NINDS, NIBIB, NIDCD, and NINR, National Institutes of Health, to invite grant applications from institutions/organizations that propose to build a research infrastructure center to promote external collaboration with the medical rehabilitation community. The aim of this FOA is to create a national network of research centers that provide access to collateral expertise in biomedical, behavioral, engineering, and/or psychosocial fields that are particularly relevant to medical rehabilitation research and the needs of people with chronic physical disabilities. Specifically, the NIH is interested in addressing gaps in the rehabilitation research portfolio and is particularly interested in the following high-priority areas: pediatric rehabilitation; personalized medicine approaches; family, caregiver, and community support; implementation and dissemination research; clinical trial design and combinatorial therapies; strategies to explore and validate combination therapies; and, technology to track real-world outcomes.
Funding Opportunity RFA-FD-19-007 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity is to solicit applications to conduct studies that could support the approval of label changes to establish more targeted durations of use for certain approved medically important antimicrobial new animal drugs in food animals. These cooperative agreements are intended to provide publicly available data to be used by sponsor(s) of affected approved new animal drugs to support approval of future supplemental new animal drug applications. Such supplemental new animal drug applications are intended to: 1) Revise approved dosage regimens to provide for use durations that are more targeted (i.e., are more specifically defined) and, 2) That the revised dosage regimens continue to provide effectiveness that is comparable to the currently approved regimen while reducing the risk of antimicrobial resistance development.
Funding Opportunity PAR-19-220 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. Through the support of trial readiness studies, NINDS and NCATS expect to enhance the quality and increase the likelihood of success of clinical trials in these rare diseases.
Funding Opportunity PAR-19-216 from the NIH Guide for Grants and Contracts. The goal of this program is to support the advancement of regulatory science to facilitate the implementation and the assessment of continuous manufacturing and similar innovative monitoring and control techniques in the pharmaceutical sector. This will be accomplished by making awards to institutions of higher education and nonprofit organizations for the purpose of studying and recommending improvements to the process of continuous manufacturing of drugs and biological products (e.g., monoclonal antibodies and therapeutic enzymes). Examples of activities could include the development or modification of a novel manufacturing process (e.g., design, scale-up, and/or commercial scale), control method, and/or testing technology. Awards made under this FOA may be funded in part by appropriations received under the 21st Century Cures Act, section 3016.